AAAAAA
Results: 276-300/1363
Authors:
Krystkowiak, P
Citation: P. Krystkowiak, Evaluation scales for Parkinson's disease (text by the bibliography group), REV NEUROL, 156, 2000, pp. 52-62
Authors:
Mauduit, N
Schuck, S
Allain, H
Chaperon, J
Citation: N. Mauduit et al., Rating scales and questionnaires in Parkinson's disease, REV NEUROL, 156, 2000, pp. 63-69
Authors:
Bonnet, AM
Citation: Am. Bonnet, Rating scales for Parkinson's disease: when and how to use them, REV NEUROL, 156, 2000, pp. 70-75
Authors:
Tison, F
Citation: F. Tison, Contribution and limitations of evaluation scales in Parkinson's disease, REV NEUROL, 156, 2000, pp. 76-80
Authors:
Derkinderen, P
Citation: P. Derkinderen, Therapeutic strategies recommended for early stage Parkinson's disease, REV NEUROL, 156, 2000, pp. 82-90
Authors:
Broussolle, E
Citation: E. Broussolle, Dopa-therapy in the treatment of early stage Parkinson's disease, REV NEUROL, 156, 2000, pp. 91-97
Authors:
Rascol, O
Montastruc, JL
Citation: O. Rascol et Jl. Montastruc, Role of dopaminergic agonists, REV NEUROL, 156, 2000, pp. 98-104
Authors:
Damier, P
Citation: P. Damier, What strategies are recommended for early stage disease? Other treatments, REV NEUROL, 156, 2000, pp. 105-108
Authors:
Destee, A
Citation: A. Destee, Parkinson's disease: what therapeutic strategy is advisable in early stagedisease?, REV NEUROL, 156, 2000, pp. 109-118
Authors:
Brefel-Courbon, C
Citation: C. Brefel-courbon, What drug strategies are advisable for patients with advanced-stage Parkinsons's (working session), REV NEUROL, 156, 2000, pp. 120-159
Authors:
Marion, MH
Citation: Mh. Marion, Drug treatments and motor complications in advanced stage Parkinson's disease, REV NEUROL, 156, 2000, pp. 160-164
Authors:
Pollak, P
Tranchant, C
Citation: P. Pollak et C. Tranchant, Other symptoms of advanced stage Parkinson's disease, REV NEUROL, 156, 2000, pp. 165-173
Authors:
Gayraud, D
Citation: D. Gayraud, Re-education and Parkinson's disease, REV NEUROL, 156, 2000, pp. 175-189
Authors:
Pelissier, J
Perennou, D
Citation: J. Pelissier et D. Perennou, Exercice program and rehabilitation of motor disorders in Parkinson's disease., REV NEUROL, 156, 2000, pp. 190-200
Authors:
Bleton, JP
Citation: Jp. Bleton, Role of rehabilitation Parkinson's disease, by disease severity and disability pattern., REV NEUROL, 156, 2000, pp. 201-210
Authors:
Ziegler, M
Citation: M. Ziegler, Reeducation of communication disorders and ENT function., REV NEUROL, 156, 2000, pp. 211-215
Citation: Economic aspects of treating Parkinson's Disease, REV NEUROL, 156, 2000, pp. 215-216
Authors:
Thobois, S
Citation: S. Thobois, Surgical treatments in Parkinson's disease, REV NEUROL, 156, 2000, pp. 218-250
Authors:
Defer, GL
Citation: Gl. Defer, Surgical treatment: inclusion criteria, REV NEUROL, 156, 2000, pp. 251-256
Authors:
Blond, S
Touzet, G
Krystkowiak, P
Defebvre, L
Destee, A
Citation: S. Blond et al., Neurosurgical treatment of Parkinson's disease: which technique is best?, REV NEUROL, 156, 2000, pp. 257-269
Authors:
Benabid, AL
Pollak, P
Citation: Al. Benabid et P. Pollak, Cost assessment of functional neurosurgery for abnormal movement by stimulation of the basal nuclei, particularly the subthalamic nucleus, REV NEUROL, 156, 2000, pp. 270-273
Citation: Jury recommendations: Consensus document - Short text, REV NEUROL, 156, 2000, pp. 274-280
Citation: Jury recommendations: Consensus document - Long text, REV NEUROL, 156, 2000, pp. 281-294
Authors:
Hugon, J
Esclaire, F
Terro, F
Yardin, C
Citation: J. Hugon et al., Apoptosis and Alzheimer's disease: contribution of cellular and transgenicmodels, REV NEUROL, 156(2), 2000, pp. 123-125
Authors:
Le Masson, G
Citation: G. Le Masson, Neuronal and synaptic properties: fundamentals of network plasticity., REV NEUROL, 156(2), 2000, pp. 127-136